Drug Profile
Gimeracil/oteracil/tegafur/folinic acid - Taiho Pharmaceuticals
Alternative Names: Folinic acid/S-1; Gimeracil/oteracil potassium/tegafur/calcium folinate; Gimeracil/oteracil potassium/tegafur/folinic acid; Gimeracil/oteracil/tegafur/calcium folinate; Gimeracil/oteracil/tegafur/leucovorin; S-1/folinic acid; TAS 118Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics; Chemoprotectants; Chemosensitisers; Formyltetrahydrofolates; Furans; Pyridines; Pyrimidinones; Small molecules; Triazines; Vitamins
- Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Gastric cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 26 Aug 2020 Discontinued - Phase-I for Solid tumours in Japan (PO) (Otsuka pharmaceuticals pipeline June 2020)
- 26 Aug 2020 Discontinued - Phase-III for Gastric cancer (Combination therapy, First-line therapy, Late-stage disease) in South Korea, Japan (PO) (Otsuka pharmaceuticals pipeline June 2020)
- 26 Aug 2020 Discontinued - Phase-III for Pancreatic cancer (Refractory metastatic disease) in Japan, South Korea (PO) (Otsuka pharmaceuticals pipeline June 2020)